Published in J Clin Immunol on January 01, 2004
Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy (2009) 1.08
Genetic deficiency of Irgm1 (LRG-47) suppresses induction of experimental autoimmune encephalomyelitis by promoting apoptosis of activated CD4+ T cells. FASEB J (2010) 0.98
Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation. Clin Exp Immunol (2012) 0.84
Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes. Autoimmune Dis (2010) 0.83
Peripheral blood lymphocyte apoptosis and its relationship with thyroid function tests in adolescents with hyperthyroidism due to Graves' disease. Arch Med Sci (2012) 0.78
Optical imaging of mitochondrial redox state in rodent models with 3-iodothyronamine. Exp Biol Med (Maywood) (2013) 0.76
Altered regulatory mechanisms governing cell survival in children affected with clustering of autoimmune disorders. Ital J Pediatr (2012) 0.75
Mitochondria and apoptosis. Science (1998) 23.41
The biochemistry of apoptosis. Nature (2000) 18.91
Functional diversity of helper T lymphocytes. Nature (1996) 18.09
Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell (1998) 16.08
The Bcl-2 protein family: arbiters of cell survival. Science (1998) 16.08
Apoptosis by death factor. Cell (1997) 14.42
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature (1998) 8.93
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 8.23
Caspases: intracellular signaling by proteolysis. Cell (1997) 7.46
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med (1986) 6.11
Apoptosis in the nervous system. Nature (2000) 5.82
Double identity for proteins of the Bcl-2 family. Nature (1997) 5.60
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
CD95's deadly mission in the immune system. Nature (2000) 5.55
Sex differences in autoimmune disease. Nat Immunol (2001) 5.08
Insulin-dependent diabetes mellitus. Cell (1996) 5.06
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science (2001) 4.89
Mitochondrial control of apoptosis. Immunol Today (1997) 4.74
Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem (1999) 4.56
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Apoptosis. Immunol Today (1993) 4.23
The Th1/Th2 paradigm. Immunol Today (1997) 3.96
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med (1996) 3.56
Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell (1996) 3.48
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol (1990) 3.35
Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev (2001) 3.31
Multiple sclerosis: a two-stage disease. Nat Immunol (2001) 3.20
Interferon-gamma induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol (1985) 3.18
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature (1985) 3.11
CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A (1999) 3.07
Defying death after DNA damage. Nature (2000) 3.03
Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci (2001) 3.03
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet (1996) 3.00
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol (2000) 2.98
Apoptosis in development. Nature (2000) 2.95
The genetics of complex autoimmune diseases: non-MHC susceptibility genes. Nat Immunol (2001) 2.87
Host defense, viruses and apoptosis. Cell Death Differ (2001) 2.84
Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev (1994) 2.80
TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80
The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol (1998) 2.60
Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science (1997) 2.56
Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol (1996) 2.55
Apoptotic DNA fragmentation. Exp Cell Res (2000) 2.52
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci U S A (1997) 2.50
Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol (1993) 2.45
A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol (2002) 2.31
The role of Fas in autoimmune diabetes. Cell (1997) 2.30
Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem (1998) 2.25
Autoimmune diseases: the failure of self tolerance. Science (1990) 2.24
Autoimmune thyroid disease: further developments in our understanding. Endocr Rev (1994) 2.19
Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med (1995) 2.15
Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci U S A (1998) 2.04
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest (2000) 2.00
T-cell recognition of myelin basic protein. Immunol Today (1991) 1.98
Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes (2001) 1.95
Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol (2003) 1.87
Th1/Th2 cells. Inflamm Bowel Dis (1999) 1.86
Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol (2002) 1.85
Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol (1993) 1.81
The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol (1998) 1.78
FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci U S A (2002) 1.72
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest (1997) 1.69
Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol (1998) 1.62
Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol (2001) 1.61
Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med (1997) 1.55
IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J Immunol (2001) 1.55
Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med (1996) 1.53
Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med (1997) 1.51
Islet beta-cell apoptosis triggered in vivo by interleukin-1beta is not related to the inducible nitric oxide synthase pathway: evidence for mitochondrial function impairment and lipoperoxidation. Endocrinology (2003) 1.39
Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J Immunol (1999) 1.35
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med (1996) 1.34
Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med (1997) 1.33
Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J Clin Invest (2000) 1.31
Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 1.30
Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia (1996) 1.29
The role of autoantibodies in autoimmune disease. Annu Rev Immunol (1993) 1.28
Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol (2002) 1.27
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest (1997) 1.21
Cell death mediators in autoimmune diabetes--no shortage of suspects. Cell (1997) 1.20
Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol (2001) 1.20
Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol (2003) 1.16
Clearing the way to mechanisms of autoimmunity. Nat Med (2001) 1.13
Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable pathway in rat insulin-producing cells. Endocrinology (2000) 1.13
Autoimmunity and apoptosis: the Crohn's connection. Immunity (2001) 1.11
Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol (1999) 1.10
Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol (2002) 1.10
Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. Diabetes (2003) 1.08
Role of apoptosis in pancreatic beta-cell death in diabetes. Diabetes (2001) 1.07
Comment on "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease". Science (2003) 1.06
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 7.05
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47
Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.18
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Colon cancer stem cells: promise of targeted therapy. Gastroenterology (2010) 2.58
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood (2011) 2.20
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res (2010) 2.12
Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol (2009) 1.76
Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging. Stem Cells (2015) 1.75
Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res (2010) 1.73
Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature (2006) 1.59
Islet beta-cell apoptosis triggered in vivo by interleukin-1beta is not related to the inducible nitric oxide synthase pathway: evidence for mitochondrial function impairment and lipoperoxidation. Endocrinology (2003) 1.39
Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol (2013) 1.37
Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res (2010) 1.36
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology (2010) 1.36
Human fetal aorta contains vascular progenitor cells capable of inducing vasculogenesis, angiogenesis, and myogenesis in vitro and in a murine model of peripheral ischemia. Am J Pathol (2007) 1.31
IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle (2007) 1.29
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J (2004) 1.27
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol (2010) 1.20
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol (2004) 1.18
The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab (2006) 1.18
Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res (2005) 1.15
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res (2006) 1.15
CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur J Immunol (2004) 1.15
Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res (2008) 1.15
Isolation and culture of colon cancer stem cells. Methods Cell Biol (2008) 1.13
Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res (2006) 1.13
Efficient production by sperm-mediated gene transfer of human decay accelerating factor (hDAF) transgenic pigs for xenotransplantation. Proc Natl Acad Sci U S A (2002) 1.12
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol (2013) 1.11
Therapeutic implications of Cancer Initiating Cells. Expert Opin Biol Ther (2009) 1.11
Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. FASEB J (2004) 1.09
Mechanisms underlying lineage commitment and plasticity of human γδ T cells. Cell Mol Immunol (2012) 1.07
Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol (2005) 1.05
Carbon monoxide improves cardiac energetics and safeguards the heart during reperfusion after cardiopulmonary bypass in pigs. FASEB J (2004) 1.04
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab (2007) 1.01
Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells (2012) 1.00
Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas. PLoS One (2012) 0.99
MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res (2007) 0.99
cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. J Biol Chem (2004) 0.96
Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res (2013) 0.95
NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum (2005) 0.95
Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J Biol Chem (2003) 0.93
IL-21 regulates the differentiation of a human γδ T cell subset equipped with B cell helper activity. PLoS One (2012) 0.93
TGFβ-dependent epithelial-to-mesenchymal transition is required to generate cardiospheres from human adult heart biopsies. Stem Cells Dev (2012) 0.89
Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy. Cancer Res (2009) 0.88
Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity. PLoS One (2013) 0.88
p63 isoforms regulate metabolism of cancer stem cells. J Proteome Res (2014) 0.87
Colorectal cancer stem cells and cell death. Cancers (Basel) (2011) 0.87
Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol (2013) 0.86
CD133 as a target for colon cancer. Expert Opin Ther Targets (2012) 0.85
Evidences of cervical cancer stem cells derived from established cell lines. Cell Cycle (2010) 0.84
Distribution, function and predictive value of tumor-infiltrating γδ T lymphocytes. Oncoimmunology (2013) 0.82
Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor. Clin Cancer Res (2011) 0.82
Immunotherapy targeting colon cancer stem cells. Immunotherapy (2011) 0.80
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. Cancer Lett (2010) 0.80
Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. Am J Hematol (2013) 0.79
Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. Oncoimmunology (2013) 0.78
Therapeutic targeting of cancer stem cells. Front Oncol (2011) 0.76
Colon Cancer Stem Cells: Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease Breakdown. Cancers (Basel) (2011) 0.76
High levels of exogenous C2-ceramide promote morphological and biochemical evidences of necrotic features in thyroid follicular cells. J Cell Biochem (2002) 0.76
γδ T cells as a potential tool in colon cancer immunotherapy. Immunotherapy (2014) 0.76
Betulinic Acid Kills Colon Cancer Stem Cells. Curr Stem Cell Res Ther (2016) 0.75